Results 61 to 70 of about 1,044,846 (392)

The release of platelet-activating factor from human endothelial cells in culture.

Journal of Immunology, 1983
The release of platelet-activating factor (PAF) from stimulated human endothelial cells (HEC) cultured from normal term, umbilical cord veins is described.
G. Camussi, M. Aglietta, F. Malavasi, C. Tetta, W. Piacibello, F. Sanavio, F. Bussolino   +6 more
semanticscholar   +1 more source

Protease-activated receptor 1 mediates thrombin-dependent, cell-mediated renal inflammation in crescentic glomerulonephritis. [PDF]

, 2000
Protease-activated receptor (PAR)-1 is a cellular receptor for thrombin that is activated after proteolytic cleavage. The contribution of PAR-1 to inflammatory cell-mediated renal injury was assessed in murine crescentic glomerulonephritis (GN).
Bernatowicz, Bohm, Bradford, Connolly, Cunningham, Erlich, Grandaliano, Holdsworth, Huang, Ishihara, Kahn, Li, Mari, Mueller, Naish, Neale, Nicholson, Nystedt, Rasmussen, Rydel, Shankar, Stone, Taylor, Taylor, Thomson, Tipping, Tipping, Tipping, Ueno, Vu, Vu, Woolkalis, Xu, Xu   +33 more
core   +3 more sources

Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression

Molecular Oncology, EarlyView.
Circulating tumor DNA (ctDNA) offers a possibility for different applications in early and late stage breast cancer management. In early breast cancer tumor informed approaches are increasingly used for detecting molecular residual disease (MRD) and early recurrence. In advanced stage, ctDNA provides a possibility for monitoring disease progression and
Eva Valentina Klocker, Samantha Hasenleithner, Rupert Bartsch, Simon P. Gampenrieder, Daniel Egle, Christian F. Singer, Gabriel Rinnerthaler, Michael Hubalek, Katja Schmitz, Zsuzsanna Bago‐Horvath, Andreas Petzer, Sonja Heibl, Ellen Heitzer, Marija Balic, Michael Gnant   +14 more
wiley   +1 more source

Platelet activating factor revisited [PDF]

Thorax, 1997
8A2 and acetyltransferase on membrane alkylacyl phospholipids. PAF was found to possess many properties that made it well suited as a proinflammatory mediator of inflammation in many inflammatory diseases. 1 Interest in Degradation of PAF its potential role as a mediator of asthma was fuelled Being a potent bioactive mediator, it makes sense that PAF ...
openaire   +3 more sources

Prolonged Exposure to Platelet Activating Factor Transforms Breast Epithelial Cells

Frontiers in Genetics, 2021
Lipid species are known to have various biological functions owing to their structural differences, and each of them possesses a specific role to play depending upon their location and distribution in the cell. Some of these lipids interact with proteins
Vaishali Chakravarty, Libi Anandi, K. A. Ashiq, K. Abhijith, Rintu Umesh, Mayurika Lahiri   +5 more
doaj   +1 more source

Physicochemical and functional identity of rabbit platelet-activating factor (PAF) released in vivo during IgE anaphylaxis with PAF released in vitro from IgE sensitized basophils.

Journal of Immunology, 1979
Platelet activating factor (PAF) released in vivo into the plasmas of rabbits during development of IgE-induced systemic anaphylactic shock had indistinguishable physicochemical and functional properties when compared with PAF released in vitro from ...
R. Neal Pinckard, Richard S. Farr, Donald J. Hanahan   +2 more
semanticscholar   +1 more source

Receptor-independent metabolism of platelet-activating factor by myelogenous cells [PDF]

, 1989
Human neutrophils incorporate and metabolize platelet-activating factor (PAF). We dissociated these events from PAF binding to its receptors. Cells were pretreated with either pronase, a PAF antagonist (L652731), or excess PAF.
Chabot, Marie C., Jacobson, David, O'Flaherty, Joseph T., Redman, Jimmy, Wykle, Robert L.   +4 more
core   +1 more source

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

Molecular Oncology, EarlyView.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha, Steven Kao, Veronica K. Cheung, Wendy A. Cooper, Nico van Zandwijk, John E. J. Rasko, Dannel Yeo   +6 more
wiley   +1 more source

Human endothelial cells in culture produce platelet-activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when stimulated with thrombin.

Proceedings of the National Academy of Sciences of the United States of America, 1984
Cultured human endothelial cells produce platelet-activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine; PAF) when stimulated with human thrombin. The response to thrombin is dose dependent, with a half-maximal effect at 0.17 unit/ml.
S. Prescott, G. Zimmerman, T. McIntyre
semanticscholar   +1 more source

Identification of Functional Platelet-Activating Factor Receptors on Human Keratinocytes [PDF]

, 1995
Platelet-activating factor (PAP) is a potent inflammatory mediator that has been shown to be produced by human keratinocytes and is thought to play a role in cutaneous inflammation, Immunofluorescence and radioligand binding studies were used to ...
Archer, Barr, Bass, Berridge, Bligh, Boukamp, Bradford, Braquet, Chilton, Csato, Fisher, Haslam, Honda, Inarrea, Kemeny, Leprince, Levesque, MacDougall, Mallet, Malone, Mazer, Michel, Muller, Nakamura, Nishizuka, O'Flaherty, Okubo, Ono, Pignol, Prescott, Saunders, Scatchard, Shukla, Stoll, Travers, Travers, Tripathi, Yohn   +37 more
core   +1 more source